BioTissue Holdings Inc.

BioTissue Holdings Inc. is a regenerative medicine company specializing in cryopreserved human birth tissue allografts for ocular and surgical applications. The company's proprietary CryoTek® technology preserves the structure and biological function of amniotic membrane and umbilical cord tissue, enabling regenerative healing in ophthalmology and wound care. The ocular division offers Prokera (self-adhesive amniotic membrane), CAM360 AmnioGraft, AmnioGraft, and AmnioGuard for corneal surface disease, dry eye, and other ocular conditions. The surgical division (recently divested to BioStem Technologies as of January 2026) previously offered Neox and Clarix products for soft tissue reconstruction and wound healing. BioTissue maintains over 40 years of research and development with more than 1 million human clinical applications and 420 peer-reviewed publications supporting product efficacy. The company operates a physician portal for healthcare professionals, manages donor tissue procurement through its Sharing Miracles program, and provides comprehensive clinical support including reimbursement assistance and medical inquiry services. Products are cryopreserved for extended shelf life and distributed through a network of local sales representatives and customer service teams. The company emphasizes regulatory compliance and maintains accreditation standards for tissue banking and processing.